pharmaceuticals - Publications - Faculty & Research - Harvard Business School

Filter Results: (1,248)

Filter Results: (1,248)

Show Results For

← Page 43 of 1,248 Results →

April 2023
Case

Elliott Management: Capital Allocation in Biopharma

By: Amitabh Chandra, Paul Clancy and Lauren Gunasti

The case explores the intersection of capital allocation and shareholder activism in the biopharmaceutical industry. As many biopharma companies face looming patent expirations for key medicines, the case asks the question of whether investing in R&D and M&A is an... View Details

Keywords: Finance; Strategy; Capital Allocation; Biopharmaceutical Industry; Shareholder Activism; Investment Activism; Resource Allocation; Research and Development; Business and Shareholder Relations; Corporate Strategy; Pharmaceutical Industry

October 2020
Teaching Plan

Merck: COVID-19 Vaccines

By: Willy C. Shih

COVID-19 infections were still climbing across the U.S. and many other parts of the world in September 2020, and it seemed that every time Ken Frazier, the CEO of Merck & Co. consented to an interview in recent months he always seemed to hear the same question,... View Details

Keywords: Vaccines; Health Pandemics; Health Testing and Trials; Innovation and Management; Innovation Strategy; Research and Development; Business Strategy; Pharmaceutical Industry; United States

January 2017
Supplement

Medtronic: Making the Big Leap Forward (B)

By: William W. George and Monica Baraldi

On December 1, 2014, Medtronic announced that it had completed a $17 billion bond sale to finance the Covidien acquisition, officially completed on January 26, 2015. Medtronic’s legal headquarters moved to Ireland, while its operational headquarters remained in... View Details

Keywords: Acquisition; Medtronic; Covidien; Mission; Tax Inversion; Business Strategy; Leadership; Mergers and Acquisitions; Integration; Pharmaceutical Industry; Republic of Ireland; Europe; Minnesota; United States

December 2014 (Revised October 2017)
Case

Social Business at Novartis: Arogya Parivar

By: Michael E. Porter, Mark R. Kramer and David Lane

Late in 2013, Novartis CEO Joseph Jimenez was considering whether or how to deepen the company's investment in Arogya Parivar, its profitable program that sold Novartis medicines in rural India while expanding access to medicine and health information to millions of... View Details

Keywords: Shared Value; India; Kenya; Vietnam; Novartis; Arogya Parivar; Social Business; Multinational Firms and Management; Competitive Advantage; Corporate Social Responsibility and Impact; Pharmaceutical Industry; Viet Nam; Kenya; India

March 2014
Editorial

Limits on Use of Health Economic Assessments for Rare Diseases

By: Hanna I. Hyry, Ariel Dora Stern, Jonathan CP Roos and Timothy M. Cox

Funding of expensive treatments for rare ('orphan') diseases is contentious. These agents fare poorly on 'efficiency' or health economic measures, such as the QALY, because of high cost and frequently poor gains in quality of life and survival. We show that... View Details

Keywords: Cost; Health Disorders; Health Care and Treatment; Pharmaceutical Industry

Find at Harvard

April 2014 (Revised July 2015)
Case

Sanofi Pasteur: The Dengue Vaccine Dilemma

By: V. Kasturi Rangan, David E. Bloom, Vincent Dessain and Emilie Billaud

In 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a... View Details

Keywords: Health Testing and Trials; Product Launch; Market Entry and Exit; Emerging Markets; Pharmaceutical Industry; France

October 1994
Case

Nippon Kayaku

By: Robin Cooper, Takeo Yoshikawa and Robert S. Kaplan

Keywords: Pharmaceutical Industry; Japan

Find at Harvard

2013
Working Paper

Visualizing and Measuring Enterprise Architecture: An Exploratory BioPharma Case

By: Robert Lagerstrom, Carliss Baldwin, Alan MacCormack and David Dreyfus

We test a method that was designed and used previously to reveal the hidden internal architectural structure of software systems. The focus of this paper is to test if it can also uncover new facts about the components and their relationships in an enterprise... View Details

Keywords: Complexity; Applications and Software; Product Design; Pharmaceutical Industry

September 2012 (Revised November 2014)
Case

Cialis Lifecycle Management: Lilly's BPH Dilemma

By: Elie Ofek and Natalie Kindred

How should Eli Lilly further develop and market a new indication of its highly successful erectile-dysfunction (ED) drug, Cialis, without confusing Cialis's hard-won brand equity with physicians and patients? With the final stages of clinical trials for the new... View Details

Keywords: Product Positioning; Attitudes; Brands and Branding; Pharmaceutical Industry; United States

May 2011 (Revised July 2012)
Exercise

Remicade/Simponi: Confidential Instructions for Merck

By: Guhan Subramanian and Rhea Ghosh

This two-party negotiation exercise features a real-life dispute between Merck and Johnson & Johnson regarding European distribution rights to two highly lucrative drugs. View Details

Keywords: Price; Rights; Agreements and Arrangements; Negotiation Deal; Problems and Challenges; Risk and Uncertainty; Pharmaceutical Industry

December 2010
Teaching Note

Organization and Strategy at Millennium (TN) (A) & (B)

By: Julie M. Wulf

Teaching Note for 710-415 and 710-418. View Details

Keywords: Competitive Strategy; Crisis Management; Organizational Change and Adaptation; Pharmaceutical Industry

July 2009 (Revised May 2010)
Case

Pfizer: Letter from the Chairman (A)

By: Robert L. Simons and Natalie Kindred

This case explores maximizing shareholder value as a goal in executive decision making. Over a period of nine years, three different Pfizer CEOs make critical decisions intended to increase shareholder value. But the results are disappointing. To allow students to... View Details

Keywords: Decision Choices and Conditions; Corporate Accountability; Corporate Governance; Annual Reports; Business and Shareholder Relations; Value Creation; Pharmaceutical Industry; United States

April 2009
Teaching Note

Amylin Pharmaceuticals: Diabetes and Beyond (TN)

By: Richard G. Hamermesh and Rachel Gordon

Teaching Note for [809011]. View Details

Keywords: Negotiation Deal; Product Development; Success; Commercialization; Governing Rules, Regulations, and Reforms; Resource Allocation; Pharmaceutical Industry

April 2009
Supplement

Merck: Managing Vioxx (G)

By: Robert L. Simons and Natalie Kindred

Keywords: Decision Choices and Conditions; Leadership; Customer Focus and Relationships; Pharmaceutical Industry

April 2009 (Revised April 2010)
Supplement

Merck: Managing Vioxx (F)

By: Robert L. Simons and Natalie Kindred

Keywords: Health; Pharmaceutical Industry

April 2009
Supplement

Merck: Managing Vioxx (D)

By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred

Keywords: Pharmaceutical Industry

April 2009
Supplement

Merck: Managing Vioxx (C)

By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred

Keywords: Pharmaceutical Industry

April 2009 (Revised April 2010)
Supplement

Merck: Managing Vioxx (B)

By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred

Keywords: Health; Pharmaceutical Industry

2008
Case

Eli Lilly: Recreating Drug Discovery for the 21st Century

By: Rebecca Henderson and C. Reavis

Keywords: Innovation and Invention; Health Care and Treatment; Pharmaceutical Industry

May 2006
Teaching Note

WuXi PharmaTech (TN)

By: Richard G. Hamermesh and Erin Seefeld

Keywords: Pharmaceutical Industry

←
43
44
…
62
63
→